Levetiracetam Tablet, Film Coated, Extended Release
Product Images NDC 71205-881

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Levetiracetam (NDC 71205-881). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Levetiracetam 01)

Chemical structure of Levetiracetam, the active ingredient in Levetiracetam ER tablets. The diagram shows the molecular components and arrangement typical of Levetiracetam's chemical formula.*

FDA Label Image

Figure 1 (Levetiracetam 02)

A bar chart showing the percentage of patients across three groups: Placebo (7.4%), Immediate-release levetiracetam 1,000 mg/day (37.1%), and Immediate-release levetiracetam 3,000 mg/day (39.6%). The y-axis represents % of patients ranging up to 45%, with each bar labeled with the corresponding percentage and patient count in each group.*

FDA Label Image

Figure 2 (Levetiracetam 03)

A bar graph showing the percentage of patients on three different treatments: Placebo, Immediate-release levetiracetam 1,000 mg/day, and Immediate-release levetiracetam 2,000 mg/day. Percentages increase from approximately 6.3% on placebo, to 20.8% on 1,000 mg/day, and 35.2% on 2,000 mg/day. Sample sizes (N) for each group are indicated below the bars.*

FDA Label Image

Figure 3 (Levetiracetam 04)

A bar chart comparing the percentage of patients for two groups: placebo (N=104) and immediate-release levetiracetam 3,000 mg/day (N=180). The placebo group shows 14.4% of patients, and the immediate-release levetiracetam group shows 39.4% of patients. The chart highlights the difference in patient percentages between these two groups.*

FDA Label Image

Figure 4 (Levetiracetam 05)

A bar chart comparing the percentage of patients between placebo and immediate-release levetiracetam groups from a clinical study. The x-axis shows two groups: placebo (N=97) and immediate-release levetiracetam (N=101). The y-axis represents the percentage of patients, with bars indicating approximately 19.6% for placebo and 44.6% for immediate-release levetiracetam.*

FDA Label Image

71205-880-30 (Levetiracetam 06)

Label for Levetiracetam ER 500 mg extended release oral tablets by Proficient Rx LP. The label states 30 film-coated tablets with a once daily dosing instruction. It includes the product ID, manufacturer ScieGen Pharmaceuticals, and storage conditions (20°-25°C). Tablets are oval-shaped, debossed with 'SG' and '189'.*

FDA Label Image

71205-881-30 (Levetiracetam 07)

Label for Levetiracetam 750 mg extended-release oral tablets by Proficient Rx LP, packaged in a quantity of 30. The label notes that each film-coated tablet contains 750 mg of levetiracetam, USP, describes the tablets as white, oval-shaped, film-coated with specific debossing, and includes storage instructions and manufacturer details from ScieGen Pharmaceuticals, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.